Praxis Precision Medicines (PRAX) News Today $76.55 +0.35 (+0.46%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$76.55 0.00 (0.00%) As of 01/31/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Piper Sandler Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)February 1 at 5:04 AM | markets.businessinsider.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $149.11 Consensus Price Target from BrokeragesFebruary 1 at 1:23 AM | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Moderate Buy" from AnalystsPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and eight have assigned aJanuary 29 at 2:25 AM | marketbeat.comTruist Financial Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) StockJanuary 23, 2025 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Up 8.5% on Analyst UpgradeJanuary 23, 2025 | americanbankingnews.comJefferies maintains Praxis stock with $305 target, bullish on catalystsJanuary 22, 2025 | msn.comTruist Financial Releases a Buy Rating on Praxis Precision Medicines (PRAX)January 21, 2025 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Praxis Precision Medicines (PRAX)January 21, 2025 | markets.businessinsider.comExpert Outlook: Praxis Precision Medicine Through The Eyes Of 5 AnalystsJanuary 21, 2025 | benzinga.comTruist raises Praxis stock target to $175 on study optimismJanuary 21, 2025 | msn.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Up 8.5% Following Analyst UpgradePraxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 8.5% on Analyst UpgradeJanuary 21, 2025 | marketbeat.comTruist Financial Issues Positive Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock PriceTruist Financial lifted their target price on Praxis Precision Medicines from $150.00 to $175.00 and gave the stock a "buy" rating in a research note on Tuesday.January 21, 2025 | marketbeat.comEllsworth Advisors LLC Invests $627,000 in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Ellsworth Advisors LLC purchased a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 8,150 shares of the company's stock, valued at approximately $627,000. Other hedge funds aJanuary 21, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Short Interest UpdatePraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 1,900,000 shares, an increase of 24.2% from the December 15th total of 1,530,000 shares. Currently, 11.0% of the company's stock are short sold. Based on an average trading volume of 329,800 shares, the short-interest ratio is presently 5.8 days.January 18, 2025 | marketbeat.comAssenagon Asset Management S.A. Acquires 548,986 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Assenagon Asset Management S.A. boosted its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 5,437.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 559,082 shares of the comJanuary 17, 2025 | marketbeat.comPiper Sandler Keeps Their Buy Rating on Praxis Precision Medicines (PRAX)January 16, 2025 | markets.businessinsider.comPraxis Precision Medicines, Inc.: Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business PrioritiesJanuary 13, 2025 | finanznachrichten.dePraxis Precision Medicines Highlights 2025 Corporate Strategy and Business PrioritiesJanuary 12, 2025 | globenewswire.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 8.9% - Time to Sell?Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 8.9% - Time to Sell?January 10, 2025 | marketbeat.comPraxis Precision management to meet with TruistJanuary 7, 2025 | markets.businessinsider.comPraxis Precision Medicines to Present at J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | finance.yahoo.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eigJanuary 4, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by Barclays PLCBarclays PLC grew its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 126.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 37,130 shares of the company's stock after purchasing an additional 20,759 sDecember 27, 2024 | marketbeat.comPraxis Precision files automatic mixed securities shelfDecember 24, 2024 | markets.businessinsider.comPraxis Precision Medicines (PRAX) Gets a Buy from Truist FinancialDecember 20, 2024 | markets.businessinsider.comFranklin Resources Inc. Raises Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Franklin Resources Inc. boosted its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 85.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 445,233 shares of the company'sDecember 20, 2024 | marketbeat.comState Street Corp Sells 29,518 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)State Street Corp lessened its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 3.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 789,624 shares of the company's stocDecember 20, 2024 | marketbeat.comPraxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet SyndromeDecember 18, 2024 | finanznachrichten.dePraxis Precision announces U.S. FDA granted RPDD for relutrigineDecember 18, 2024 | markets.businessinsider.comPraxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet SyndromeDecember 18, 2024 | globenewswire.comPraxis Precision Medicines (NASDAQ:PRAX) Sees Large Volume Increase - Here's What HappenedPraxis Precision Medicines (NASDAQ:PRAX) Sees Strong Trading Volume - Here's What HappenedDecember 16, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by Wellington Management Group LLPWellington Management Group LLP increased its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 326.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 219,907 shares of the company's stock after buyiDecember 15, 2024 | marketbeat.comBNP Paribas Financial Markets Has $548,000 Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)BNP Paribas Financial Markets grew its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 369.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,525 shares of the company's stock after purchasing an additionaDecember 14, 2024 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)December 12, 2024 | markets.businessinsider.comExpert Ratings For Praxis Precision MedicineDecember 12, 2024 | benzinga.comPromising Pipeline and Strategic Developments Position Praxis Precision Medicines for Market ExpansionDecember 12, 2024 | markets.businessinsider.comPraxis Precision Medicines' (PRAX) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $120.00 price objective on shares of Praxis Precision Medicines in a research report on Thursday.December 12, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Position Trimmed by Fmr LLCFmr LLC decreased its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 5.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 273,895 shares of the company's stock after selling 17,084 shares during theDecember 11, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. boosted its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 188.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 137,052 shares of the compDecember 11, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight havDecember 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 23,362 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Jacobs Levy Equity Management Inc. reduced its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 36.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 39,999 shares of the company's stock after selling 23,362 shares during theDecember 8, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Acquired by Janus Henderson Group PLCJanus Henderson Group PLC lifted its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 37.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 523,566 shares of the company's stock aDecember 7, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by RA Capital Management L.P.RA Capital Management L.P. cut its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 38.3% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 761,955 shares of the company's stock after selling 473,644 sharesDecember 5, 2024 | marketbeat.comPraxis Precision Medicines to Present at Upcoming December Investor ConferencesDecember 3, 2024 | globenewswire.comHighVista Strategies LLC Takes $630,000 Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)HighVista Strategies LLC acquired a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,951 shares of the coDecember 3, 2024 | marketbeat.comWalleye Capital LLC Buys Shares of 55,613 Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Walleye Capital LLC purchased a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 55,613 shares of theDecember 3, 2024 | marketbeat.comBaker BROS. Advisors LP Purchases 191,572 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Baker BROS. Advisors LP raised its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 145.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 323,105 shares of the comDecember 2, 2024 | marketbeat.comFred Alger Management LLC Increases Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Fred Alger Management LLC raised its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 301.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,423 shares of thDecember 2, 2024 | marketbeat.comVerition Fund Management LLC Sells 189,169 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Verition Fund Management LLC trimmed its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 25.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 559,151 shares of the company'November 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Sells 80,194 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Ally Bridge Group NY LLC trimmed its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 52.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,185 shares of the comNovember 28, 2024 | marketbeat.com Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAX Media Mentions By Week PRAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRAX News Sentiment▼0.470.69▲Average Medical News Sentiment PRAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRAX Articles This Week▼54▲PRAX Articles Average Week Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Grifols News Today Axsome Therapeutics News Today TG Therapeutics News Today Krystal Biotech News Today Verona Pharma News Today Organon & Co. News Today Biohaven News Today Ultragenyx Pharmaceutical News Today Scholar Rock News Today Alvotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRAX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
